{
    "2018-02-19": [
        [
            {
                "time": "2018-01-03",
                "original_text": "What's in Store for Ligand (LGND) This Earnings Season?",
                "features": {
                    "keywords": [
                        "Ligand",
                        "earnings season"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Celgene Reports Positive Data on Dermatology Drug Otezla",
                "features": {
                    "keywords": [
                        "Celgene",
                        "Otezla",
                        "positive data"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Imfinzi",
                        "FDA nod"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Kymriah May Emerge as a Robust Treatment Option in DLBCL Indication",
                "features": {
                    "keywords": [
                        "Kymriah",
                        "DLBCL",
                        "treatment option"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "MEDIA LINK-Novartis CEO is using data science to revolutionize its drug-development pipeline -WSJ",
                "features": {
                    "keywords": [
                        "Novartis",
                        "data science",
                        "drug development"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Kymriah",
                        "gene therapy"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Is AbbVie or Gilead Sciences Stock a Better Buy?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Gilead Sciences",
                        "better buy"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "GlaxoSmithKline’s Business Segments in 4Q17",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "business segments",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Cosentyx May Change Disease Progression for Ankylosing Spondylitis",
                "features": {
                    "keywords": [
                        "Cosentyx",
                        "disease progression",
                        "Ankylosing Spondylitis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}